[Anti-rheumatoid biologics and pharmacoeconomic evaluation].
Tsutani
Kiichiro
K
Department of Pharmacoeconomics, Graduate School of Pharmaceutical Sciences, The University of Tokyo.
Igarashi
Ataru
A
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D017850:Economics, Pharmaceutical; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics* / Q000627:therapeutic use; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept